Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab mechanism of action in advanced melanoma
NCT00471887Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2007
- Primary completion
- Jul 2011
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in melanoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jan 2007; status: completed.
02
Drugs
tremelimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00471887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471887.